| Literature DB >> 26705516 |
Melissa Fisher1, Synthia H Mellon2, Owen Wolkowitz3, Sophia Vinogradov1.
Abstract
OBJECTIVE: We previously reported the interim effects in a per protocol analysis of a randomized controlled trial of an innovative neuroscience-informed computerized cognitive training approach in schizophrenia. Here we report the effects of training on behavioral outcome measures in our final sample using an intent-to-treat analysis. We also report the effects on serum brain-derived neurotrophic factor (BDNF).Entities:
Keywords: BDNF; Schizophrenia; cognitive remediation; neuroplasticity
Year: 2016 PMID: 26705516 PMCID: PMC4685735 DOI: 10.1016/j.scog.2015.10.006
Source DB: PubMed Journal: Schizophr Res Cogn ISSN: 2215-0013
Fig. 1CONSORT diagram of auditory training participants (AT) and computer games control participants (CG).
Demographics of auditory training participants (AT) and computer games control participants (CG).
| AT (N=46) | CG (N=41) | ||
|---|---|---|---|
| Mean (SD) | Mean (SD) | T-test (p-value) | |
| Male/Female | 34/12 | 29/12 | 0.11 (0.74) |
| Age | 40.70 (11.81) | 43.20 (10.62) | 1.03 (0.31) |
| Education | 13.24 (2.25) | 13.32 (1.93) | 0.17 (0.86) |
| WASI IQ | 101.11 (16.69) | 103.58 (16.24) | 0.69 (0.49) |
| PANSS Total | 73.41 (20.59) | 73.95 (15.85) | 0.14 (0.89) |
| QLS Average Item Rating | 3.10 (1.17) | 2.93 (0.95) | − 0.74 (0.46) |
| Hours of Training | 44.13 (12.34) | 39.37 (15.06) | − 1.62 (0.11) |
chi-Square results.
Positive and Negative Syndrome Scale.
Quality of Life Scale-Abbreviated.
Medication regimens of study participants.
| AT (N=46) | CG (N=41) | Total | Test Statistic | p value | |
|---|---|---|---|---|---|
| Antipsychotic Medication | |||||
| 1st Generation (N) | 2 | 5 | 7 | 0.18 | |
| 2nd Generation (N) | 33 | 29 | 62 | 0.92 | |
| Multiple (N) | 5 | 5 | 10 | 0.85 | |
| No Antipsychotic (N) | 6 | 2 | 8 | 0.19 | |
| Other Psychiatric Medication | |||||
| Antidepressants or | 24 | 20 | 44 | 0.75 | |
| Mood Stabilizers (N) | |||||
| Benzodiazepines (N) | 9 | 12 | 21 | 0.29 | |
| Other Medication Measures | |||||
| Chlorpromazine Equivalents | 346.20 (249.47) | 397.90 (297.49) | t(85) = 0.88 | 0.38 |
AT, auditory training group; CG, computer games control group.
1st Generation Antipsychotic medication = chlorpromazine, haloperidol, perphenazine, thioridazine, thiothixene.
2nd Generation Antipsychotic medication = aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone.
Mean and SD of Chlorpromazine Equivalents (Andreasen et al., 2010).
Intent to treat analysis of cognitive and clinical outcomes in auditory training participants (AT) and computer games control participants (CG).
| Outcome | AT (N=46) | CG (N=41) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Post | Baseline | Post | Effect | |||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | F | p | Size | |
| Global Cognition | − 1.10 | 0.73 | − 0.84 | 0.77 | − 0.88 | 0.77 | − 0.89 | 0.75 | 9.83 | 0.74 | |
| Speed of Processing | − 0.73 | 0.69 | − 0.50 | 0.64 | − 0.60 | 0.80 | − 0.64 | 0.86 | 5.01 | 0.51 | |
| Working Memory | − 0.74 | 1.03 | − 0.49 | 1.07 | − 0.61 | 1.12 | − 0.46 | 1.14 | 0.67 | 0.42 | 0.16 |
| Verbal Learning | − 2.39 | 1.26 | − 2.01 | 1.32 | − 1.96 | 1.10 | − 2.30 | 1.20 | 10.58 | 0.73 | |
| Verbal Memory | − 2.23 | 1.29 | − 1.66 | 1.40 | − 1.73 | 1.35 | − 2.14 | 1.35 | 13.84 | 0.85 | |
| Visual Learning | − 1.50 | 1.24 | − 1.15 | 1.45 | − 1.12 | 1.39 | − 1.03 | 1.47 | 0.59 | 0.45 | 0.21 |
| Visual Memory | − 1.14 | 1.62 | − 1.09 | 1.66 | − 0.90 | 1.72 | − 0.67 | 1.68 | 0.99 | 0.32 | − 0.14 |
| Problem Solving | − 0.09 | 0.95 | 0.01 | 0.76 | − 0.02 | 0.84 | 0.10 | 0.97 | 0.46 | 0.50 | − 0.09 |
| PANSS Total | 73.41 | 20.59 | 73.15 | 19.36 | 73.95 | 15.85 | 71.76 | 16.50 | 1.08 | 0.30 | 0.18 |
| QLS Average Item Rating | 3.10 | 1.17 | 3.16 | 1.03 | 2.93 | 0.95 | 3.17 | 0.91 | 1.86 | 0.18 | − 0.25 |
Speed of processing (symbol coding; category fluency; trails a); working memory (letter-number span; WMS-III spatial span); verbal learning (HVLT trials 1–3), verbal memory (HVLT delayed recall); visual learning (BVMT trials 1–3), visual memory (BVMT delayed recall); problem solving (BACS tower of London); and global cognition (composite score of all measures).
Repeated measures ANCOVA, condition-by-time interaction, controlling for hours of training.
Group differences remained significant with baseline entered as a covariate (p<0.01).
Positive and negative syndrome scale.
Quality of life scale-abbreviated.
Fig. 2Serum brain-derived Neurotrophic factor (BDNF) levels (ng/ml) at baseline, 2 weeks of training, and post training in auditory training participants (AT) and computer games control participants (CG).
Fig. 3Serum brain-derived Neurotrophic factor (BDNF) levels (ng/ml) at baseline, 2 weeks of training, and post training in auditory training participants (AT) and at baseline in healthy control participants.